Skip to main content
Fig. 5 | Malaria Journal

Fig. 5

From: Nrf2-driven CD36 and HO-1 gene expression in circulating monocytes correlates with favourable clinical outcome in pregnancy-associated malaria

Fig. 5

Capacity of monocytes to modulate CD36 expression in PAM. Monocytes were treated with sulforaphane (10 µM) and rosiglitazone (5 µM), two respective agonists of Nrf2 and PPARγ for 4 h before the detection of CD36 mRNA level by qRT-PCR. Left panel Monocytes sampled in women with low infant birth weights (≤2.5 kg) produced higher levels of CD36 mRNA after sulforaphane activation than monocytes related to high infant birth weight (>2.5 kg). Right panel Activation of these two groups of monocytes with rosiglitazone did not lead to any difference. Monocytes activated by sulforaphane were also compared to monocytes activated by rosiglitazone. No difference of capacity to produce CD36 mRNA was found, whatever the group of monocytes. Values were compared by the Mann–Whitney U-test

Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us